Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Abstract 17006: Is White Rice Consumption a Risk for Cardiovascular Disease? A Systematic Review and Meta-analysis
Krittanawong, Chayakrit , Tunhasiriwet, Anusith, Bisanz, Kimberly J , Zhang, Hongju, Marysia, Tweet S, Krittanawong, Chayakrit , Prokop, Larry J. , Chirapongsathorn, Sakkarin , Wang, Zhen , Hayes, Sharonne N.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17006 Get It

Introduction: Current proposed Dietary Guidelines for Americans, 2015 suggested replacing refined grains (e.g., white rice) with whole grains (e.g., brown rice) for improved health outcomes; however, the association between white rice consumption and risk of cardiovascular disease (CVD) was not fully investigated. The purpose of this study was to explore the associations between rice consumption, metabolic syndrome and cardiovascular disease. Methods: We conducted a comprehensive search of MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials from database inception through May 2015. Observational studies were included if the studies reported hazard ratios (HRs) or odd ratios (ORs) of the associations between rice consumption, metabolic syndrome and cardiovascular disease. Data were extracted by one reviewer and then reviewed by two independent reviewers. Conflicts were resolved through consensus. Using the DerSimonian and Laird random effects models, we calculated pooled HRs and pooled ORs with 95% confidence intervals (95% CIs). Subgroup analyses were performed to explore potential sources of heterogeneity. The quality of the included studies and publication bias were assessed. Results: Out of 343 retrieved articles, we identified 6 cross-sectional and 9 prospective studies with a total of 575,852 individuals with 24,649 total CVD events and 4,409 metabolic syndrome cases. The highest category of white rice consumption (≥5 times/week) was associated with a 37% higher risk of metabolic syndrome (pooled OR, 1.37; 95% CI: 1.03-1.84; p<0.001; I 2 = 78.7%) but not a higher risk of cardiovascular disease (pooled HR, 1.01; 95% CI: 0.95-1.08; p=0.65; I 2 = 0%), compared to the lowest category (≤1 time/month). Conclusions: Higher white rice consumption has not been shown to increase the risk of cardiovascular diseases but may be associated with increased risk of metabolic syndrome.
Abstract MP34: Association of Overweight and Obesity with an Incidence of Heart Failure: A Systematic Review and Meta-analysis
Krittanawong, Chayakrit , Tunhasiriwet, Anusith, Zhang, Hongju , Prokop, Larry J. , Tweet, Marysia S. , Chirapongsathorn, Sakkarin , Wang, Zhen , Sun, Tao, Hayes, Sharonne N.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 133 | Issue: suppl_1 | Pages: No page available

10.1161/circ.133.suppl_1.mp34 Get It

Introduction: Obesity is a growing global health problem associated with substantial morbidity and mortality. The risk of obesity on incident new-onset heart failure is controversial. The aim of this systematic review and meta-analysis was to explore the association between overweight, obesity and incident new-onset heart failure. Methods: We systematically searched MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials from database inception through April 2015. Prospective cohort studies were included if the studies reported hazard ratios (HRs) of the association between overweight or obesity and new-onset heart failure (HF) relative to individuals with normal weight. Data were extracted by one reviewer followed by independent screening and extraction of study characteristics and outcome data by two other reviewers. Conflicts were resolved through consensus. Random-effects meta-analyses were used to pool the hazard ratio from the included studies. Subgroup analyses were performed to explore the potential sources of heterogeneity. Results: Out of 1,865 retrieved articles, we identified 10 relevant studies. Median follow-up was 12 years with a total of 82,167 individuals and 4,570 total HF events. Compared to normal body weight (body mass index (BMI) <25 kg/m2), overweight (BMI 25-29.9 kg/m2) was associated with 27% higher risk of new-onset heart failure events (pooled HR, 1.27; 95% confidence intervals (95% CI): 1.15-1.41; p<0.001; I 2 = 0%) and obesity (BMI ≥30 kg/m2) was associated with a two-fold increased risk for new-onset heart failure events (pooled HR, 2.09; 95% CI, 1.68-2.60; p<0.001; I 2 = 67.8%). Conclusions: Compared with normal-weight individuals, both overweight and obesity were independently associated with significantly higher incidence of heart failure. These results highlight the need for better understanding of mechanisms of obesity and heart failure.
Abstract 123: The Immunoproteasome Does Not Influence Macrophage Differentiation but Survival of Differentiated Macrophages
Nesbitt, Lisa, Herrmann, Joerg , Wang, Feilong , Lerman, Amir

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 35 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.35.suppl_1.123 Get It

Background: Atherosclerosis is an inflammatory disease with T cells and macrophages as the leading plaque cell populations. The immunoproteasome (IP) influences T cell survival and differentiation but its impact on macrophage survival and differentiation remains unknown, which was the objective of this study. Methods: Murine monocyte/macrophage Raw264.7 cells were stimulated by IFN-gamma (20 ng/mL) plus LPS (10pg/mL) or IL-4 (20 ng/mL) for 18 hours to induce M1 and M2 macrophages, and these differentiated macrophages were then re-exposed to IFN- gamma and IL-4 for another 24 hours, without and with IP subunit beta 5i inhibition by siRNA or Onx0914. Nitric oxide synthase and arginase activity served as differentiation markers (analyzed by enzymatic assays) as did the cytokine/chemokine profile (analyzed by antibody arrays). Cell viability was tested by an XTT assay and apoptosis by TUNEL FACS. Results: IP beta5i knockout/inhibition did not influence M1 and M2 macrophage differentiation. Also, no significant differences in apoptosis were observed between RAW264.7 cells treated with and without beta 5i inhibitor during macrophage differentiation. With re-exposure to IFN- gamma and IL-4, however, there was more apoptosis and less survival of differentiated M1 macrophages with beta5i inhibition. Conversely, beta 5i inhibition achieved less apoptosis and more survival of differentiated M2 macrophages when switching IL-4- to IFN-gamma-stimulating conditions. Conclusions: IP inhibition does not influence macrophage differentiation but survival of differentiated macrophages of potential significance for the atherosclerotic disease process.
Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
Gao, Huanyao , Kim, Wootae , Scholz, Jodi A. , Yu, Jia , Qin, Bo , Zhuang, Yongxian , Tan, Winston , Bryce, Alan H. , Weinshilboum, Richard M. , Wang, Liewei , Xie, Fang , Bryce, Alan H , Kim, Wootae , Qin, Sisi , Zhang, Huan , Gu, Yayun , Kalari, Krishna R. , Sinnwell, Jason P. , Xie, Fang , Yin, Ping , Wei, Lixuan , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | March 15, 2022 | Volume: 111 | Issue: 6 | Pages: 1296-1306

10.1002/cpt.2582 | PMID 35288936 Get It

Approximately one‐third of patients with metastatic castration‐resistant prostate cancer (CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone nonresponders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in tumor biopsies and patient‐derived xenograft (PDX) tumors between abiraterone responders and nonresponders enrolled in PROMOTE trial. This approach identified 3 drugs, including topoisomerase II (TOP2) inhibitor mitoxantrone, CDK4/6 inhibitor palbociclib, and pan‐CDK inhibitor PHA‐793887. These drugs significantly suppressed the growth of abiraterone‐resistant cell lines and PDX models. Moreover, we identified 11 genes targeted by all 3 drugs that were associated with worse outcomes in both the PROMOTE and Stand Up To Cancer cohorts. This 11‐gene panel might also function as biomarkers to select the 3 alternative therapies for this subgroup of patients with CRPC, warranting further clinical investigation.
Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants
Athreya, Arjun P. , Voort, Jennifer L. Vande , Shekunov, Julia , Rackley, Sandra , Leffler, Jarrod M. , McKean, Alastair J. , Romanowicz, Magdalena , Emslie, Graham J. , Mayes, Taryn L. , Trivedi, Madhukar H. , Wang, Liewei , Weinshilboum, Richard M. , Vande Voort, Jennifer L., Rackley, Sandra J, Bobo, William V. , Mayes, Taryn , Kennard, Betsy D. , Weinshilboum, Richard M. , Croarkin, Paul E.

Mayo Clinic

Journal of Child Psychology and Psychiatry | March 15, 2022 | Volume: 63 | Issue: 11 | Pages: 1347-1358

10.1111/jcpp.13580 | PMID 35288932 Get It

Background The treatment of depression in children and adolescents is a substantial public health challenge. This study examined artificial intelligence tools for the prediction of early outcomes in depressed children and adolescents treated with fluoxetine, duloxetine, or placebo. Methods The study samples included training datasets ( N = 271) from patients with major depressive disorder (MDD) treated with fluoxetine and testing datasets from patients with MDD treated with duloxetine ( N = 255) or placebo ( N = 265). Treatment trajectories were generated using probabilistic graphical models (PGMs). Unsupervised machine learning identified specific depressive symptom profiles and related thresholds of improvement during acute treatment. Results Variation in six depressive symptoms (difficulty having fun, social withdrawal, excessive fatigue, irritability, low self‐esteem, and depressed feelings) assessed with the Children’s Depression Rating Scale‐Revised at 4–6 weeks predicted treatment outcomes with fluoxetine at 10–12 weeks with an average accuracy of 73% in the training dataset. The same six symptoms predicted 10–12 week outcomes at 4–6 weeks in (a) duloxetine testing datasets with an average accuracy of 76% and (b) placebo‐treated patients with accuracies of 67%. In placebo‐treated patients, the accuracies of predicting response and remission were similar to antidepressants. Accuracies for predicting nonresponse to placebo treatment were significantly lower than antidepressants. Conclusions PGMs provided clinically meaningful predictions in samples of depressed children and adolescents treated with fluoxetine or duloxetine. Future work should augment PGMs with biological data for refined predictions to guide the selection of pharmacological and psychotherapeutic treatment in children and adolescents with depression.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Lheureux, Stéphanie , Konstantinopoulos, Panagiotis A. , Wang, Ben X. , Gadalla, Ramy , Block, Matthew S. , Gaillard, Stéphanie , McHale, Michael , Werner, Theresa L. , Duska, Linda , Kehoe, Siobhan M., Colombo, Ilaria , Wang, Lisa , Wildman, Rachel P., Soleimani, Shirin , Lien, Scott , Wright, John, Pugh, Trevor J. , Pugh, Trevor J , Konstantinopoulos, Panagiotis A , Gaillard, Stéphanie , Matei, Daniela , Jewell, Andrea , McCourt, Carolyn Kay , Temkin, Sarah M. , Girda, Eugenia , Backes, Floor , Li, Xuan , Wildman, Rachel, Wright, John, Ohashi, Pamela S. , Brooks, David G. , Fleming, Gini F.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 14, 2022 | Volume: 10 | Issue: 3 | Pages: e004233

10.1136/jitc-2021-004233 | PMID 35288469 Get It

Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and an antiangiogenic agent (cabozantinib) in immunotherapy-naïve endometrial cancer and in patients whose disease progressed on previous immunotherapy with baseline biopsy for immune profiling. Patients and methods In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11, 2017), women with recurrent endometrial cancer were randomized 2:1 to nivolumab with cabozantinib (Arm A) or nivolumab alone (Arm B). The primary endpoint was Response Evaluation Criteria in Solid Tumors-defined progression-free survival (PFS). Patients with carcinosarcoma or prior immune checkpoint inhibitor received combination treatment (Arm C). Baseline biopsy and serial peripheral blood mononuclear cell (PBMC) samples were analyzed and associations between patient outcome and immune data from cytometry by time of flight (CyTOF) and PBMCs were explored. Results Median PFS was 5.3 (90% CI 3.5 to 9.2) months in Arm A (n=36) and 1.9 (90% CI 1.6 to 3.4) months in Arm B (n=18) (HR=0.59, 90% CI 0.35 to 0.98; log-rank p=0.09, meeting the prespecified statistical significance criteria). The most common treatment-related adverse events in Arm A were diarrhea (50%) and elevated liver enzymes (aspartate aminotransferase 47%, alanine aminotransferase 42%). In-depth baseline CyTOF analysis across treatment arms (n=40) identified 35 immune-cell subsets. Among immunotherapy-pretreated patients in Arm C, non-progressors had significantly higher proportions of activated tissue-resident (CD103+CD69+) ɣδ T cells than progressors (adjusted p=0.009). Conclusions Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune profile and potentially benefiting from combination with antiangiogenics requires further investigation.
Mitochondrial pyruvate carrier-mediated metabolism is dispensable for the classical activation of macrophages
Ran, Linyu, Zhang, Song , Zhao, Pei , Sun, Jiaxing , Gan, Haiyun , Li, Qiang , Herrmann, Joerg , Zhang, Song , Ran, Linyu, Zhou, Jiaqi, Jeon, Ryoung‐Hoon , Wang, Feilong

Mayo Clinic

No container title available | March 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1413776/v1 Get It

Abstract Glycolysis is essential for the classical activation of macrophages (M1), but how glycolytic pathway metabolites engage in this process remains to be elucidated. Glycolysis culminates in the production of pyruvate, which can be transported into the mitochondria by the mitochondrial pyruvate carrier (MPC) followed by conversion to citrate and utilization in the TCA cycle. Alternatively, pyruvate can be metabolized to lactate under aerobic conditions, which had been considered to be the dominant route in the setting of classical macrophage activation. However, based on studies that used UK5099 as a MPC inhibitor and showed reduction in key inflammatory cytokines, the mitochondrial route has been considered to be of significance for M1 activation as well. Herein, using a genetic depletion model, we found that MPC is dispensable for metabolic reprogramming and the activation of M1. In addition, MPC depletion in myeloid cells has no impact on inflammatory responses and macrophage polarization toward M1 phenotype in the endotoxemia mice model. While UK5099 reaches maximal MPC inhibitory capacity at approximately 2–5µM, higher concentrations are required to inhibit inflammatory cytokine production in M1 and this is independent of MPC expression. Taken together, this study found MPC-mediated metabolism is dispensable for the classical activation of macrophages, and UK5099 inhibits inflammatory responses in M1 macrophages due to effects other than MPC inhibition.
CancerBERT: a cancer domain-specific language model for extracting breast cancer phenotypes from electronic health records
Zhou, Sicheng , Wang, Nan , Wang, Liwei , Zhang, Rui , Zhang, Rui , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | March 9, 2022 | Volume: 29 | Issue: 7 | Pages: 1208-1216

10.1093/jamia/ocac040 | PMID 35333345 Get It

Abstract Objective Accurate extraction of breast cancer patients’ phenotypes is important for clinical decision support and clinical research. This study developed and evaluated cancer domain pretrained CancerBERT models for extracting breast cancer phenotypes from clinical texts. We also investigated the effect of customized cancer-related vocabulary on the performance of CancerBERT models. Materials and Methods A cancer-related corpus of breast cancer patients was extracted from the electronic health records of a local hospital. We annotated named entities in 200 pathology reports and 50 clinical notes for 8 cancer phenotypes for fine-tuning and evaluation. We kept pretraining the BlueBERT model on the cancer corpus with expanded vocabularies (using both term frequency-based and manually reviewed methods) to obtain CancerBERT models. The CancerBERT models were evaluated and compared with other baseline models on the cancer phenotype extraction task. Results All CancerBERT models outperformed all other models on the cancer phenotyping NER task. Both CancerBERT models with customized vocabularies outperformed the CancerBERT with the original BERT vocabulary. The CancerBERT model with manually reviewed customized vocabulary achieved the best performance with macro F1 scores equal to 0.876 (95% CI, 0.873–0.879) and 0.904 (95% CI, 0.902–0.906) for exact match and lenient match, respectively. Conclusions The CancerBERT models were developed to extract the cancer phenotypes in clinical notes and pathology reports. The results validated that using customized vocabulary may further improve the performances of domain specific BERT models in clinical NLP tasks. The CancerBERT models developed in the study would further help clinical decision support.
TFAM-dependent mitochondrial integrity in regulatory T cells preserves immune landscape and restrains inflammaging
Guo, Kai , Gill, Jappreet Singh, Debnath, Trishna , Bansal, Benu, Poojary, Rayansh, Correa, Jacquiline Kim, Celik, Hakan, Mehta, Het, Abrham, Eden, Even, Zachery, Rahman, Mansib, Costa, Abby Lund Da , Jain, Shilpi , Murugaiyan, Gopal , Ting, Adrian T. , Hur, Junguk , Brown‐Borg, Holly M. , Jurivich, Donald A. , Mathur, Ramkumar , Wang, Zhihan , Gill, Jappreet Singh, Bansal, Benu, Poojary, Rayansh, Correa, Jacquiline Kim, Celik, Hakan, Rahman, Mansib, Wang, Xusheng , Khan, Nadeem

Mayo Clinic

No container title available | March 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.03.08.483517 Get It

Abstract Foxp3⁺ regulatory T cells (Tregs) maintain immune homeostasis, yet the process that preserves their stability during aging remain unclear. Mechanistic progress has been hindered by models that ablate Tregs or delete Foxp3 , which induce acute autoimmunity and prevent longitudinal study of physiological regulatory drift. Here, we establish a dose-dependent mitochondrial framework that preserves Treg lineage survival while permitting gradual metabolic attenuation. Using Treg-restricted TFAM modulation, a complementary haploinsufficient model, and whole-spleen single-cell profiling. We identify lineage-selective immune remodeling characterized by contraction of naïve CD8⁺ and follicular B-cell pools, alteration of CD4⁺ states, expansion of activated Tregs, and emergence of neuroimmune stress linked transcriptional modules that parallel physiological aging. Mechanistically, mitochondrial insufficiency is associated with functional loss of FOXP3- centered chromatin coordination and enrichment of NF-κB/NFAT/AP-1 inflammatory and senescence programs while lineage identity remains detectable. Partial mitochondrial attenuation within Tregs alone is sufficient to drive chronic low-grade systemic inflammation, neuromuscular decline, gut microbial restructuring, and elevated microglial responsiveness without Treg depletion. Pharmacologic and microbiota-directed interventions partially reduce inflammatory tone and improve functional metrics. Together, our findings identify TFAM as a key regulator of immune aging and reveal that healthy mitochondrial function in Tregs is essential for protecting against inflammaging and age-associated functional decline.